zurück | Brustkrebs: Brusterhaltung - Ablatio | ||||||||||||||||||||||||||||||||||||||||||
allgemeines |
Die brusterhaltende Therapie des Mammakarzinoms ist nur zulässig, wenn kein schlechteres Überleben gegenüber der Ablatio inkauf genommen werden muss. Die Studien, die diese Fragestellung untersucht haben sind inzwischen mehrere Jahrzehnte alt, bilden aber immernoch die Grundlage der brusterhaltenden Therapie. | ||||||||||||||||||||||||||||||||||||||||||
Studien |
|
||||||||||||||||||||||||||||||||||||||||||
Quellen |
1.) Arriagada R, Le MG, Rochard F, et al.: Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 14(1996):1558–64 2.) Blichert-Toft M, Nielsen M, During M, et al.: Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 47(2008):672–81 3.) Fisher B, Anderson S, Bryant J, et al.: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(2002):1233–41 4.) Veronesi U, Cascinelli N, Mariani L, et al.: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347(2002):1227–32 5.) Litiere S, Werutsky G, Fentiman IS, et al.: Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 13(2012):412–9 6.) Poggi MM, Danforth DN, Sciuto LC, et al.: Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial. Cancer 98(2003):697–702 7.) van Dongen JA, Voogd AC, Fentiman IS, et al.: Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 92(2000):1143–50. | ||||||||||||||||||||||||||||||||||||||||||
Impressum .....................................................................................Zuletzt geändert am 26.04.2014 13:13